title: Prostaglandin F2 alpha and oxytocin interactions in ovarian and uterine function.
abstract: The oxytocin-neurophysin gene is expressed in several nontraditional sites within the endocrine system. In the ovary its expression in the corpora lutea is initiated by ovulation. Ovarian oxytocin concentrations reach maximal levels around day 11 of luteal cycle and fall to a nadir at estrus. PGF2 alpha has the capacity to release oxytocin from the corpus luteum, and oxytocin in turn releases PGF2 alpha from the uterine endometrium or decidua. This positive feedback loop between the ovary and the uterus ensures the completion of luteolysis in species that depend on the presence of the uterus for the termination of luteal lifespan. Immunization against oxytocin has been shown to disrupt this loop, resulting in much-prolonged luteal cycles. In primates and other species in which luteal life span is independent of the uterus, an oxytocin PGF2 alpha interaction may take place within the ovary itself. At parturition a related interaction takes place which ensures the expulsion of the fetus and placenta in an orderly manner. Oxytocin of both pituitary and ovarian origin reaches the uterus via its blood supply and binds to two types of receptors: one on myometrial cells, the occupation of which initiates contractions, and the other on decidual cells, the occupation of which initiates prostaglandin generation. This prostaglandin diffuses into the adjacent myometrium and augments the oxytocin-induced contractions. In conjunction with a direct softening effect by prostaglandins on the cervix the augmented contractions achieve the force needed to dilate the cervix and expel the fetus. An additional source of oxytocin during labor may be the placenta, another non-traditional site for the occurrence of oxytocin.
authors.affiliation: Cornell University Medical College, Department of Obstetrics and Gynecology, New York, NY 10021.
authors.forename: A R
authors.initials: AR
authors.lastname: Fuchs
mesh_terms: D000818:Animals; D015237:Dinoprost; D005260:Female; D006801:Humans; D007743:Labor, Obstetric / Q000502:physiology; D010053:Ovary / Q000502:physiology*; D010121:Oxytocin / Q000502:physiology*; D011247:Pregnancy; D011453:Prostaglandins / Q000502:physiology; D011460:Prostaglandins F / Q000502:physiology*; D011945:Receptors, Angiotensin / Q000502:physiology; D018045:Receptors, Oxytocin; D014599:Uterus / Q000502:physiology*
chemical_list: D011453:Prostaglandins; D011460:Prostaglandins F; D011945:Receptors, Angiotensin; D018045:Receptors, Oxytocin; D010121:Oxytocin; D015237:Dinoprost